-
公开(公告)号:US11186591B2
公开(公告)日:2021-11-30
申请号:US16818512
申请日:2020-03-13
申请人: TORQUR AG , UNIVERSITÄT BASEL
发明人: Vladimir Cmiljanovic , Paul Hebeisen , Florent Beaufils , Thomas Bohnacker , Denise Rageot , Alexander Sele , Matthias Wymann , Jean-Baptiste Langlois
IPC分类号: C07D413/14 , C07D498/08 , A61K31/53 , C07D401/14 , C07D405/14 , C07D401/04 , C07D403/04 , C07D239/48 , C07D491/048 , C07D491/056 , C07D491/20 , C07D519/00 , A61P35/00 , C07D417/14 , C07D491/107 , C07D491/18
摘要: The invention relates to novel phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and PI3K-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
-
公开(公告)号:US20220153752A1
公开(公告)日:2022-05-19
申请号:US17499048
申请日:2021-10-12
申请人: TORQUR AG , UNIVERSITÄT BASEL
发明人: Vladimir CMILJANOVIC , Paul HEBEISEN , Florent BEAUFILS , Thomas BOHNACKER , Denise RAGEOT , Alexander SELE , Matthias WYMANN , Jean-Baptiste LANGLOIS
IPC分类号: C07D498/08 , A61K31/53 , C07D401/14 , C07D405/14 , C07D413/14 , C07D401/04 , C07D403/04 , C07D239/48 , C07D491/048 , C07D491/056 , C07D491/20 , C07D519/00 , A61P35/00 , C07D417/14 , C07D491/107 , C07D491/18
摘要: The invention relates to novel phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and PI3K-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
-
公开(公告)号:US11918586B2
公开(公告)日:2024-03-05
申请号:US17214309
申请日:2021-03-26
发明人: Doriano Fabbro , Paul Hebeisen , Petra Hillmann-Wuellner , Anton Stuetz , John T. Seykora , Florent Beaufils
IPC分类号: A61K31/5377 , A61K31/5386 , A61K31/541 , A61P17/02
CPC分类号: A61K31/5377 , A61K31/5386 , A61K31/541 , A61P17/02
摘要: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1 X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue-R8R9— selected from Ci-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2— or —O—CH2CH2—O—; with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a skin lesion in a subject.
-
公开(公告)号:US20240343718A1
公开(公告)日:2024-10-17
申请号:US18526732
申请日:2023-12-01
申请人: TORQUR AG , UNIVERSITÄT BASEL
发明人: Denise RAGEOT , Paul HEBEISEN , Florent BEAUFILS , Doriano FABBRO , Petra HILLMAN-WULLNER , Hoa Huu Phuc NGUYEN , Wolfgang LOSCHER , Claudia BRANDT , Alexander Markus SELE
IPC分类号: C07D413/14 , A61K31/53 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61P25/08 , A61P25/28 , C07D417/14 , C07D451/02 , C07D451/14 , C07D498/08 , C07D519/00
CPC分类号: C07D413/14 , A61K31/53 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61P25/08 , A61P25/28 , C07D417/14 , C07D451/02 , C07D451/14 , C07D498/08 , C07D519/00
摘要: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1X2 and X3 are N; Y is N or CH; R1 and R2 are independently of each other (iii) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fhioroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(0)0-C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6- selected from Ci-C3alkylene optionally substituted with 1 to 4 F, —CH2-0-CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (iv) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence Ci-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3 alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue —R8R9— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2-0-CH2— or —O—CH2CH2-0-; with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a neurological disorder in a subject.
-
公开(公告)号:US11878972B2
公开(公告)日:2024-01-23
申请号:US17125012
申请日:2020-12-17
申请人: TORQUR AG , UNIVERSITÄT BASEL
发明人: Denise Rageot , Paul Hebeisen , Florent Beaufils , Doriano Fabbro , Petra Hillmann-Wüllner , Hoa Huu Phuc Nguyen , Wolfgang Löscher , Claudia Brandt , Alexander Markus Sele
IPC分类号: C07D413/14 , A61P25/28 , A61P25/08 , C07D417/14 , C07D451/02 , C07D451/14 , C07D498/08 , C07D519/00 , A61K31/5386 , A61K31/541 , A61K31/5377 , A61K31/53
CPC分类号: C07D413/14 , A61K31/53 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61P25/08 , A61P25/28 , C07D417/14 , C07D451/02 , C07D451/14 , C07D498/08 , C07D519/00
摘要: The present invention is relates to a compound of formula (I),
wherein
X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of
X1, X2 and X3 are N;
Y is N or CH;
R1 and R2 are independently of each other
(iii) a morpholinyl of formula (II)
wherein the arrow denotes the bond in formula (I); and
wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures
wherein the arrows denote the bonds in formula (II); or
(iv) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R 7 substituents form together a bivalent residue —R8R9— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2— or —O—CH2CH2—O—;
with the proviso that at least one of R1 and R2 is a morpholinyl of formula II;
and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof,
for use in the prevention or treatment of a neurological disorder in a subject.-
公开(公告)号:US20230014057A1
公开(公告)日:2023-01-19
申请号:US17854630
申请日:2022-06-30
申请人: TORQUR AG
IPC分类号: C07D491/08 , C07D413/14 , C07D417/14 , C07D491/16
摘要: The present invention relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(0)0-C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2-0-CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue —R8R9— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2-0-CH2— or -0-CH2CH2-0- with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in a method of treating a skin disorder in a subject, wherein said skin disorder is a genodermatosis, a vascular anomaly or a skin disorder selected from scleroderma, sclerodermatous chronic graft-versus-host disease, lichen sclerosus, lichen planus, lichen ruber planus and scars.
-
公开(公告)号:US20210361665A1
公开(公告)日:2021-11-25
申请号:US17214309
申请日:2021-03-26
发明人: Doriano FABBRO , Paul HEBEISEN , Petra HILLMANN-WUELLNER , Anton STUETZ , John T. SEYKORA , Florent BEAUFILS
IPC分类号: A61K31/5377 , A61P17/02 , A61K31/5386 , A61K31/541
摘要: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1 X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, ClalkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue —R8R9— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2— or —O—CH2CH2—O—; with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a skin lesion in a subject.
-
-
-
-
-
-